Curated News
By: NewsRamp Editorial Staff
May 16, 2024

Recce Pharmaceuticals Administers Highest Dose in Phase I/II UTI Urosepsis Trial

Reddit Discuss on RedditDiscuss on Substack SubstackView History of this news story on GitHub Github
Source News Release

TLDR

  • Recce Pharmaceuticals administers highest dose of R327 in Phase I/II UTI and urosepsis trial, positioning them at the forefront of infection treatment development.
  • RECCE® 327, an intravenous and topical therapy, is being developed to treat serious infections caused by Gram-positive and Gram-negative bacteria, including their superbug forms, with various infusion times and dosage levels being explored.
  • The development of RECCE® 327 to treat serious infections caused by resistant bacteria has the potential to make the world a better place by addressing the growing concern of antibiotic resistance.
  • RECCE® 327 marks a significant milestone in infection treatment development, with the potential to revolutionize the way serious infections caused by bacteria are treated.

Impact - Why it Matters

The progress in Recce Pharmaceuticals' clinical trial for UTI and urosepsis treatment signifies a potential breakthrough in combating serious bacterial infections, including superbug forms. The successful administration of the highest dosage of R327 in the trial to date is a significant milestone, with potential regulatory implications. This development holds promise for the future of intravenous and topical therapies in the treatment of bacterial infections, highlighting the importance of ongoing research and innovation in the pharmaceutical industry.

Summary

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has administered the first doses in the latest cohort of its Phase I/II clinical trial for urinary tract infection (UTI) and urosepsis treatment with RECCE® 327 (R327). Both male and female participants received R327 at 4,000mg intravenously (I.V.) over 20 minutes, marking the highest dosage in this trial to date. R327 is being developed to treat serious infections caused by Gram-positive and Gram-negative bacteria, including their superbug forms. The clinical trial has explored various infusion times for R327, including 15, 20, 30, and 45 minutes, across different dosage levels. This latest cohort involves the highest dose of 4,000mg, with Minimum Inhibitory Concentration (MIC) activity against bacteria identified in existing clinical samples. Remaining participants will be dosed in the coming days, and the full potential of R327 via I.V. administration will be evaluated upon completion of the trial.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Recce Pharmaceuticals Administers Highest Dose in Phase I/II UTI Urosepsis Trial

blockchain registration record for the source press release.